Multiplexed targeted mass spectrometry assays for prostate cancer-associated urinary proteins

Tujin Shi; Sue-Ing Quek; Yuqian Gao; Carrie D. Nicora; Song Nie; Thomas L. Fillmore; Tao Liu; Karin D. Rodland; Richard D. Smith; Robin J. Leach; Ian M. Thompson; Elizabeth A. Vitello; William J. Ellis; Alvin Y. Liu; Wei-Jun Qian

doi:10.18632/oncotarget.21710

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Multiplexed targeted mass spectrometry assays for prostate cancer-associated urinary proteins

Tujin Shi, Sue-Ing Quek, Yuqian Gao, Carrie D. Nicora, Song Nie, Thomas L. Fillmore, Tao Liu, Karin D. Rodland, Richard D. Smith, Robin J. Leach, Ian M. Thompson, Elizabeth A. Vitello, William J. Ellis, Alvin Y. Liu and Wei-Jun Qian _

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2017; 8:101887-101898. https://doi.org/10.18632/oncotarget.21710

Metrics: PDF 1835 views | HTML 2631 views | ?

Abstract

Tujin Shi1, Sue-Ing Quek2,3,6, Yuqian Gao1, Carrie D. Nicora1, Song Nie1, Thomas L. Fillmore4, Tao Liu1, Karin D. Rodland1, Richard D. Smith1, Robin J. Leach5, Ian M. Thompson5, Elizabeth A. Vitello2,3, William J. Ellis2, Alvin Y. Liu2,3 and Wei-Jun Qian1

1Biological Sciences Division, Pacific Northwest National Laboratory, Richland, WA, USA

2Department of Urology, University of Washington, Seattle, WA, USA

3Institute for Stem Cell and Regenerative Medicine, University of Washington, Seattle, WA, USA

4Environmental Molecular Sciences Laboratory, Pacific Northwest National Laboratory, Richland, WA, USA

5Department of Urology and the Cancer Therapy and Research Center, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA

6Present address: Singapore Polytechnic, Center for Biomedical and Life Sciences T11A-412 (level 4), Singapore

Correspondence to:

Wei-Jun Qian, email: [email protected]

Alvin Y. Liu, email: [email protected]

Keywords: secreted protein biomarkers; prostate cancer detection; prostate cancer; targeted mass spectrometry; selected reaction monitoring

Received: May 05, 2017 Accepted: August 04, 2017 Published: October 09, 2017

ABSTRACT

Biomarkers for effective early diagnosis and prognosis of prostate cancer are still lacking. Multiplexed assays for cancer-associated proteins could be useful for identifying biomarkers for cancer detection and stratification. Herein, we report the development of sensitive targeted mass spectrometry assays for simultaneous quantification of 10 prostate cancer-associated proteins in urine. The diagnostic utility of these markers was evaluated with an initial cohort of 20 clinical urine samples. Individual marker concentration was normalized against the measured urinary prostate-specific antigen level as a reference of prostate-specific secretion. The areas under the receiver-operating characteristic curves for the 10 proteins ranged from 0.75 for CXL14 to 0.87 for CEAM5. Furthermore, MMP9 level was found to be significantly higher in patients with high Gleason scores, suggesting a potential of MMP9 as a marker for risk level assessment. Taken together, our work illustrated the feasibility of accurate multiplexed measurements of low-abundance cancer-associated proteins in urine and provided a viable path forward for preclinical verification of candidate biomarkers for prostate cancer.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 21710

Publication Alerts

Research Papers:

Multiplexed targeted mass spectrometry assays for prostate cancer-associated urinary proteins

Abstract